Prognostic value of serial galectin-3 measurements in patients with acute heart failure

Journal of the American Heart Association

Volumn 6, Issue 12, 2017, Pages

  van Vark, Laura C ^a   Lesman Leegte, Ivonne ^b   Baart, Sara J ^a   Postmus, Douwe ^b   Pinto, Yigal M ^c   de Boer, Rudolf A ^b   Asselbergs, Folkert W ^d,e,f   Wajon, Elly M C J ^g   Orsel, Joke G ^h   Boersma, Eric ^a   Hillege, Hans L ^b   Martijn Akkerhuis, K ^a   Nagelsmit, Michiel J ⁱ   Brunner La Rocca, Hans Peter ^j   Linssen, Gerard C M ^k   Terpstra, Willem F ^l   Akkerhuis, K Martijn ^a   Liem, Anho H ^m   Wardeh, Alexander J ⁿ   van Miltenburg, Addy J M ^o   van den Bos, Ewout J ^p   de Ridder, Stijn P J ^q   more..

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e INTERUNIVERSITY CARDIOLOGY INSTITUTE OF THE NETHERLANDS   (Netherlands)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g MEDISCH SPECTRUM TWENTE   (Netherlands)

^h PHILIPS RESEARCH LABORATORIES   (Netherlands)

ⁱ Treant Zorggroep Scheperziekenhuis Emmen   (Netherlands)

^j MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^k Twenteborg Ziekenhuis Almelo   (Netherlands)

^l SLINGELAND HOSPITAL   (Netherlands)

^m Admiraal de Ruyter Ziekenhuis Goes   (Netherlands)

ⁿ Haaglanden MC Den Haag   (Netherlands)

^o Fransiscus Gasthuis and Vlietland Rotterdam   (Netherlands)

^p Albert Schweitzer Ziekenhuis Dordrecht   (Netherlands)

^q ST ANNA HOSPITAL   (Netherlands)

more..

Author keywords

Biomarker; Galectin 3; Heart failure; Repeated measurements

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; GALECTIN 3; BIOLOGICAL MARKER; GALECTIN-3, HUMAN;

ACUTE HEART FAILURE; AGED; ALL CAUSE MORTALITY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROGNOSIS; ACUTE DISEASE; BLOOD; CAUSE OF DEATH; CLINICAL TRIAL; EPIDEMIOLOGY; HEART FAILURE; MORTALITY; MULTICENTER STUDY; PROSPECTIVE STUDY; SURVIVAL RATE; TRENDS; VERY ELDERLY;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; BIOMARKERS; CAUSE OF DEATH; FEMALE; GALECTIN 3; HEART FAILURE; HUMANS; MALE; NETHERLANDS; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 85038832118     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.116.003700     Document Type: Article

References (31)

1. Lok DJ, Van Der Meer P, de la Porte PW, Lipsic E, Van Wijngaarden J, Hillege HL, van Veldhuisen DJ. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol. 2010;99:323-328
2. Ueland T, Aukrust P, Broch K, Aakhus S, Skardal R, Muntendam P, Gullestad L. Galectin-3 in heart failure: high levels are associated with all-cause mortality. Int J Cardiol. 2011;150:361-364
3. van Kimmenade RR, Januzzi JL Jr, Ellinor PT, Sharma UC, Bakker JA, Low AF, Martinez A, Crijns HJ, MacRae CA, Menheere PP, Pinto YM. Utility of aminoterminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol. 2006;48:1217-1224
4. Januzzi JL Jr, Sakhuja R, O'Donoghue M, Baggish AL, Anwaruddin S, Chae CU, Cameron R, Krauser DG, Tung R, Camargo CA Jr, Lloyd-Jones DM. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med. 2006;166:315-320
5. Braunwald E. Heart failure. JACC Heart Fail. 2013;1:1-20
6. TRIAL ID: NTR1893. TRanslational Initiative on Unique and novel strategies for Management of Patients with Heart failure (TRIUMPH)
7. Barondes SH, Castronovo V, Cooper DNW, Cummings RD, Drickamer K, Felzi T, Gitt MA, Hirabayashi J, Hughes C, Kasai K-I, Leffler H, Liu F-T, Lotan R, Mercurio AM, Monsigny M, Pillai S, Poirer F, Raz A, Rigby PWJ, Rini JM, Wang JL. Galectins: a family of animal beta-galactoside-binding lectins. Cell. 1994;76:597-598
8. Barondes SH, Cooper DN, Gitt MA, Leffler H. Galectins. Structure and function of a large family of animal lectins. J Biol Chem. 1994;269:20807-20810
9. Henderson NC, Sethi T. The regulation of inflammation by galectin-3. Immunol Rev. 2009;230:160-171
10. Frangogiannis NG. The immune system and cardiac repair. Pharmacol Res. 2008;58:88-111
11. Liu YH, D'Ambrosio M, Liao TD, Peng H, Rhaleb NE, Sharma U, Andre S, Gabius HJ, Carretero OA. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growthregulatory lectin. Am J Physiol Heart Circ Physiol. 2009;296:H404-H412
12. Hughes RC. The galectin family of mammalian carbohydrate-binding molecules. Biochem Soc Trans. 1997;25:1194-1198
13. de Boer RA, Yu L, van Veldhuisen DJ. Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep. 2010;7:1-8
14. Ho JE, Liu C, Lyass A, Courchesne P, Pencina MJ, Vasan RS, Larson MG, Levy D. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol. 2012;60:1249-1256
15. de Boer RA, van Veldhuisen DJ, Gansevoort RT, Muller Kobold AC, van Gilst WH, Hillege HL, Bakker SJ, van der Harst P. The fibrosis marker galectin-3 and outcome in the general population. J Intern Med. 2012;272:55-64
16. Felker GM, Fiuzat M, Shaw LK, Clare R, Whellan DJ, Bettari L, Shirolkar SC, Donahue M, Kitzman DW, Zannad F, Pina IL, O'Connor CM. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ Heart Fail. 2012;5:72-78
17. Bayes-Genis A, de Antonio M, Vila J, Penafiel J, Galan A, Barallat J, Zamora E, Urrutia A, Lupon J. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. J Am Coll Cardiol. 2014;63:158-166
18. Chen A, Hou W, Zhang Y, Chen Y, He B. Prognostic value of serum galectin-3 in patients with heart failure: a meta-analysis. Int J Cardiol. 2015;182:168-170
19. Anand IS, Rector TS, Kuskowski M, Adourian A, Muntendam P, Cohn JN. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur J Heart Fail. 2013;15:511-518
20. van der Velde AR, Gullestad L, Ueland T, Aukrust P, Guo Y, Adourian A, Muntendam P, van Veldhuisen DJ, de Boer RA. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ Heart Fail. 2013;6:219-226
21. Motiwala SR, Szymonifka J, Belcher A, Weiner RB, Baggish AL, Sluss P, Gaggin HK, Bhardwaj A, Januzzi JL. Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. Eur J Heart Fail. 2013;15:1157-1163
22. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A; Guidelines ESCCfP. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787-1847
23. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med. 2006;354:2473-2483
24. Rizopoulos D. arXiv:1404.7625. 2015. April 30, 2014
25. Lok DJ, Klip IT, Lok SI, Bruggink-Andre de la Porte PW, Badings E, van Wijngaarden J, Voors AA, de Boer RA, van Veldhuisen DJ, van der Meer P. Incremental prognostic power of novel biomarkers (growth-differentiation factor-15, high-sensitivity C-reactive protein, galectin-3, and high-sensitivity troponin-T) in patients with advanced chronic heart failure. Am J Cardiol. 2013;112:831-837
26. Zhang Y, Zhang R, An T, Huang Y, Guo X, Yin S, Wang Y, Ji S, Lv R, Zhang J, Maisel A. The utility of galectin-3 for predicting cause-specific death in hospitalized patients with heart failure. J Card Fail. 2015;21:51-59
27. Gullestad L, Ueland T, Kjekshus J, Nymo SH, Hulthe J, Muntendam P, McMurray JJ, Wikstrand J, Aukrust P. The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Am Heart J. 2012;164:878-883
28. Milting H, Ellinghaus P, Seewald M, Cakar H, Bohms B, Kassner A, Korfer R, Klein M, Krahn T, Kruska L, El Banayosy A, Kramer F. Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J Heart Lung Transplant. 2008;27:589-596
29. Kim HN, Januzzi JL Jr. Natriuretic peptide testing in heart failure. Circulation. 2011;123:2015-2019
30. de Boer RA, Lok DJ, Jaarsma T, van der Meer P, Voors AA, Hillege HL, van Veldhuisen DJ. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med. 2011;43:60-68
31. de Boer RA, van der Velde AR, Mueller C, van Veldhuisen DJ, Anker SD, Peacock WF, Adams KF, Maisel A. Galectin-3: a modifiable risk factor in heart failure. Cardiovasc Drugs Ther. 2014;28:237-246